NASDAQ
05.09.25 | 22:00
0,390 US-Dollar
+0,85 % +0,003
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.08. | Athira Pharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.08. | Athira Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | Athira Pharma, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| ATHIRA PHARMA Aktie jetzt für 0€ handeln | |||||
| 13.05. | Athira Pharma, Inc.: Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit | 1 | GlobeNewswire (USA) | ||
| 09.05. | Athira Pharma GAAP EPS of -$0.23 beats by $0.01 | 2 | Seeking Alpha | ||
| 09.05. | Athira Pharma, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 09.05. | Athira Pharma, Inc.: Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates | 426 | GlobeNewswire (Europe) | Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing... ► Artikel lesen | |
| 09.05. | Athira Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.12.24 | Athira Pharma, Inc.: Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND | 503 | GlobeNewswire (Europe) | BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and... ► Artikel lesen | |
| 07.11.24 | Athira Pharma, Inc.: Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates | 334 | GlobeNewswire (Europe) | BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and... ► Artikel lesen | |
| 01.11.24 | Pre-market Movers: ESSA Pharma, Theriva Biologics, VS MEDIA, Lexicon Pharmaceuticals, Athira Pharma | 1.290 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15.
VS... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | - | - | Boehringer Ingelheim Limited: Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases | · Collaboration strengthens Boehringer's pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an... ► Artikel lesen | |
| BIOXXMED | 0,300 | 0,00 % | PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025 | DJ PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
bioXXmed AG: Ergebnis für... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| OCUGEN | 0,882 | +0,98 % | Ocugen, Inc. - 8-K, Current Report | ||
| INFLARX | 1,366 | -3,33 % | H.C. Wainwright assumes coverage on Inflarx stock with Buy rating | ||
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| BIO-GATE | 0,900 | 0,00 % | EQS-DD: Bio-Gate AG: Karl Richter, Zeichnung von Wandelschuldverschreibungen | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
21.08.2025 / 17:58... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,465 | +4,73 % | Defence Therapeutics Inc.: Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth | Montreal, Quebec--(Newsfile Corp. - September 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in... ► Artikel lesen | |
| VAXART | 0,272 | -2,02 % | Vaxart, Inc.: Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors | ||
| BURCON NUTRASCIENCE | 1,520 | +7,04 % | Burcon NutraScience Corporation: Burcon Achieves First Commercial Production of Puratein(R)C Canola Protein | Vancouver, British Columbia--(Newsfile Corp. - September 4, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,830 | -3,01 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | 0,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland | Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
Ampligen... ► Artikel lesen | |
| IMMUNIC | 0,640 | -1,08 % | EQS-News: Immunic AG: Immunic to Participate in Investor and Scientific Conferences in September | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor and Scientific Conferences in September
04.09.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities |
Das Unternehmen ATHIRA PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,003 (+0,85 %) liegt der Kurs bei 0,390 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ATHIRA PHARMA INC finden Sie auf Wallstreet Online.